Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
RESEARCH TOOLSreports
TriSalus Life Sciences (TLSI) Stock Price & Analysis
22 Followers
TLSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.32 - $16.24
Previous Close$5.4
Volume17.79K
Average Volume (3M)42.83K
Market Cap
$158.06M
Enterprise Value$154.09M
Total Cash (Recent Filing)$3.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.42
Shares Outstanding27,159,327
10 Day Avg. Volume34,666
30 Day Avg. Volume42,831
Standard Deviation0.20
R-Squared0.02
Alpha-0.00125
Financial Highlights & Ratios
Price to Book (P/B)-4.29
Price to Sales (P/S)8.35
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.17
Enterprise Value/Gross Profit9.69
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$14.67Price Target Upside181.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
TriSalus Life Sciences News
PremiumCompany Announcements
TriSalus Life Sciences Expands Board, Welcomes Liselotte Hyveled
PremiumCompany Announcements
TriSalus Life Sciences Secures $50 Million Loan FacilityBulls Say, Bears Say
Bulls Say
Capital StructureManagement made a strategic move to strengthen its capital structure as the company continues to advance the TriNav commercial business and the nelitolimod clinical programs.
Clinical Trial ResultsTriSalus Life Sciences, Inc. presented efficacy and safety data from the 23 patient lead-in cohort for its Phase Ib PERIO-02 trial of lead asset nelitolimod in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Market ExpansionTLSI continues to expect to launch a larger-sized version of its device, which should expand its addressable market by approximately 25%.
Bears Say
Clinical TrialsThree patients (13%) reported serious treatment-related adverse events (SAEs) and one presented dose-limiting toxicity (DLT); all were in Cohort C.
Stock PerformanceShares of TLSI traded down from the close of $9.54 just prior to the exchange offer announcement.
Trading BehaviorWarrant holders that planned on exchanging their warrants for shares were likely selling shares short in advance of the exchange.
---
Ownership Overview
31.34% Insiders
0.97% Mutual Funds
2.88% Other Institutional Investors
64.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.32 and its highest was $16.24 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
Currently, no data Available
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 12, 2024 which is in 118 days.
How were TriSalus Life Sciences’s earnings last quarter?
Currently, no data Available
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 29,269,700 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Among the largest hedge funds holding TriSalus Life Sciences’s share is Duquesne Family Office LLC. It holds TriSalus Life Sciences’s shares valued at 3M.
---
TriSalus Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (181.47% Upside)
$14.67 (181.47% Upside)
Blogger Sentiment
Bearish
TLSI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 316.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.82%
Trailing 12-Months
Company Description
TriSalus Life Sciences
MedTech Acquisition Corp is a blank check company.
---
TLSI Earnings Call
Q1 2024
0:00 / 0:00
---
TLSI Stock 12 Month Forecast
Average Price Target
$14.67
▲(181.47% Upside)
Technical Analysis
Best Analysts Covering TLSI
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-18.00%
reiterated a buy rating 16 days ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -18.00% per trade.
---